Joseph Lutaakome
ID: UNCST-2020-R008323
|
An open-label, roll-over study with rilpivirine in combination with a background regimen containing other antiretrovirals (ARVs) in human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatric studies
REFNo: HS1013ES
Primary Endpoint
The primary objective of the study is to provide continued access to RPV, however there is no primary endpoint defined for this study.
Secondary Endpoint
The secondary endpoints are applicable for all subjects until data collection is terminated, as indicated.
Major Secondary Endpoints
The proportion of subjects experiencing adverse events (AEs) considered to be at least possibly related to RPV, AEs leading to discontinuation, serious adverse events (SAEs), pregnancies, and grade 3/4 rash regardless of causality throughout the study. Results of routine safety laboratory tests will only be collected if related to these types of AEs.
Other Secondary Endpoint
The proportion of subjects maintaining viral suppression (ie, <50 HIV-1 RNA copies/mL) based on available viral load data throughout the study. In case of virologic failure, emergence of resistance will also be evaluated based on available genotype/phenotype data.
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Jennifer Serwanga
ID: UNCST-2024-R002056
|
Preparation of an Inactivated covid-19 vaccine at UVRI for pre-clinical evaluations at COVAB and an Outsourced primate centre
REFNo: HS1018ES
Collect nasopharyngeal swab of circulating virus strains
b. Isolate local and globally representative wildtype SARS-CoV2 stocks
c. Generate inactivated SARS-CoV-2 products (The Vaccine).
d. Generate SARS-CoV-2 and other b-CoVs pseudovirus stocks
e. Develop assays to distinguish SARS-CoV-2 binding antibodies
f. Develop assays to distinguish SARS-CoV-2 functional neutralizing antibodies
g. Assess inactivated vaccine in Humanized ACE2 mice challenge models
h. Challenge Macaque models to assess safety, immunogenicity and protectiveness
i. Assess immunized mice for vaccine-induced antibody responses
j. Assess immunized mice for vaccine induced cellular responses
k. Assess immunized mice plasma for inflammatory responses
l. Immuno/histopathology of immunized mice organs/tissues
m. Train and develop capacity for skill transfer
The research questions are;
• Will the inactivated vaccine protect challenged mice against developing COVID-19
disease?
• Will the vaccine elicit potent neutralizing antibodies against diverse SARS-CoV-2
strains and how potent are these antibodies?
• Will the vaccine protect the challenged mice against severe inflammatory responses
and organ pathology?
• Will the inactivated vaccine elicit potent and protective effector T -Cell responses?
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Athanansio Bashaija
ID:
|
Occupational Stress, Hope, and Alcohol Use among Secondary School Teachers in Greater Bushenyi, Uganda
REFNo: SS671ES
To examine the level of occupational stress among secondary school teachers in Greater Bushenyi.
To assess the level of alcohol use among secondary school teachers in Greater Bushenyi.
To examine the level of hope among secondary school teachers in Greater Bushenyi.
To determine the relationship between occupational stress and alcohol use among secondary school teachers in Greater Bushenyi.
To establish the moderation effect of hope on the relationship between occupational stress and alcohol use among secondary school teachers in Greater Bushenyi.
|
Uganda |
2021-02-05 |
2024-02-05 |
Social Science and Humanities |
|
Degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease (IMR-SCD-301)
REFNo: HS1119ES
Primary Objectives:
1. To evaluate the HbF response to IMR-687 versus placebo
2. To evaluate the safety of IMR-687 versus placebo
Secondary Efficacy Objectives:
1. To evaluate the effect of IMR-687 versus placebo on HbF-associated biomarkers
2. To evaluate the effect of IMR-687 versus placebo on indices of red cell hemolysis
3. To evaluate the effect of IMR-687 versus placebo on indices of RBC adhesion
4. To evaluate the effect of IMR-687 versus placebo on the incidence of VOCs
5. To evaluate the effect of IMR-687 versus placebo on quality of life (QoL) measures
Pharmacokinetic Objectives:
To evaluate the PK of IMR-687 and any major circulating metabolites
Exploratory Efficacy Objectives:
1. To evaluate the effect of IMR-687 versus placebo on changes in RBC characteristics and total Hb
2. To evaluate the effect of IMR-687 versus placebo on renal function
3. To evaluate the effect of IMR-687 versus placebo on indices associated with cardiovascular pathophysiology and ischemic stroke risk
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Sheila Balinda Nina
ID: UNCST-2021-R013804
|
Novel Adenovirus-based Vaccine for Uganda SARS COV-2 viruses
REFNo: HS1153ES
To develop a Novel SARS-Cov-2 Adeno-Vectored Vaccine against COVID-19. Briefly, we propose two adenovirus vector constructs using both S1 and S2 SARS-CoV-2 glycoproteins previously generated for the subunit vaccine design at CoVAB. Alternatively, these genes can also be amplified directly from the genome at the UVRI laboratories. Although most of the world is focused on SARS-CoV-2 Spike as an antigen, there are additional viral capsid proteins that should also be considered including the Envelope and N proteins.
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|